Global Cord Blood (NYSE:CORBF) vs. Sotera Health (NASDAQ:SHC) Critical Survey

Sotera Health (NASDAQ:SHC) and Global Cord Blood (NYSE:CORBF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Institutional & Insider Ownership

91.0% of Sotera Health shares are owned by institutional investors. 55.1% of Sotera Health shares are owned by company insiders. Comparatively, 0.5% of Global Cord Blood shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Sotera Health and Global Cord Blood, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0	1	4	0	2.80
Global Cord Blood	0	0	0	0	N/A

Sotera Health currently has a consensus target price of $17.70, indicating a potential upside of 57.05%. Given Sotera Health’s higher probable upside, research analysts clearly believe Sotera Health is more favorable than Global Cord Blood.

Volatility and Risk

Sotera Health has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500.

Earnings & Valuation

This table compares Sotera Health and Global Cord Blood’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.05 billion	3.04	$51.38 million	$0.18	62.61
Global Cord Blood	$196.12 million	N/A	$79.04 million	N/A	N/A

Global Cord Blood has lower revenue, but higher earnings than Sotera Health.

Profitability

This table compares Sotera Health and Global Cord Blood’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sotera Health	4.90%	51.32%	6.49%
Global Cord Blood	N/A	N/A	N/A

Summary

Sotera Health beats Global Cord Blood on 9 of the 10 factors compared between the two stocks.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

About Global Cord Blood

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.